Arrowhead Published New Findings from 2 P-II (SHASTA-2 & MUIR) studies for Plozasiran at AHA 2023
Shots:
- In SHASTA-2 study (n=226) of plozasiran in patients with SHTG (with TG > 500 mg/dL), two doses of 10 mg, 25 mg, or 50 mg Q12W reduced TGs and 90% patients achieved TG levels <500 mg/dL.
- At 24 wks, plozasiran decreased serum APOC3 to -79%, TGs to -74%, and remnant cholesterol to -63%, while increasing HDL-cholesterol to +68% and showed favorable safety profile
- In MUIR study (n=353) of plozasiran in subjects with mixed dyslipidemia (fasting TGs: 150-499 mg/dL & either LDL-cholesterol >70 mg/dL or non-HDL-cholesterol>100 mg/dL), similar doses at Q12W or Q24W, silenced APOC3 and robust reductions in atherogenic lipoproteins observed. At 24 wks, plozasiran reduced TGs to -64%, remnant cholesterol to -54%, ApoB to -19%, and Non-HDL-cholesterol to -27%, while increasing HDL-cholesterol to +51%
Ref: Arrowhead | Image: Arrowhead
Related News:- Arrowhead and Janssen Entered into a Licensing Agreement with GSK for JNJ-3989 to Treat Chronic Hepatitis B
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Shivani is a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
